Do the Benefits of COVID‐19 Policies Exceed the Costs? Exploring Uncertainties in the Age–VSL Relationship

Numerous analyses of the benefits and costs of COVID‐19 policies have been completed quickly as the crisis has unfolded. The results often largely depend on the approach used to value mortality risk reductions, typically expressed as the value per statistical life (VSL). Many analyses rely on a population‐average VSL estimate; some adjust VSL for life expectancy at the age of death. We explore the implications of theory and empirical studies, which suggest that the relationship between age and VSL is uncertain. We compare the effects of three approaches: (1) an invariant population‐average VSL; (2) a constant value per statistical life‐year (VSLY); and (3) a VSL that follows an inverse‐U pattern, peaking in middle age. We find that when applied to the U.S. age distribution of COVID‐19 deaths, these approaches result in average VSL estimates of $10.63 million, $4.47 million, and $8.31 million. We explore the extent to which applying these estimates alters the conclusions of frequently cited analyses of social distancing, finding that they significantly affect the findings. However, these analyses do not address other characteristics of COVID‐19 deaths that may increase or decrease the VSL estimates. Examples include the health status and income level of those affected, the size of the risk change, and the extent to which the risk is dreaded, uncertain, involuntarily incurred, and outside of one's control. The effects of these characteristics and their correlation with age are uncertain; it is unclear whether they amplify or diminish the effects of age on VSL.

[1]  J. Hammitt Valuing mortality risk in the time of COVID-19 , 2020, Journal of Risk and Uncertainty.

[2]  Victor Chernozhukov,et al.  A Multi-Risk SIR Model with Optimally Targeted Lockdown , 2020 .

[3]  Jason F. Shogren,et al.  The Benefits and Costs of Using Social Distancing to Flatten the Curve for COVID-19 , 2020, Journal of Benefit-Cost Analysis.

[4]  Cdc Covid- Response Team Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 — United States, February 12–March 28, 2020 , 2020 .

[5]  Emily N. Ussery,et al.  Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 — United States, February 12–March 28, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[6]  Michael Greenstone,et al.  Does Social Distancing Matter? , 2020 .

[7]  Jason F. Shogren,et al.  The Benefits and Costs of Using Social Distancing to Flatten the Curve for COVID-19 , 2020, Journal of Benefit-Cost Analysis.

[8]  J. Hammitt,et al.  Valuing Children’s Fatality Risk Reductions , 2019, Journal of Benefit-Cost Analysis.

[9]  Joseph E. Aldy,et al.  Birds of a feather: Estimating the value of statistical life from dual-earner families , 2019, Journal of Risk and Uncertainty.

[10]  W. Viscusi Pricing Lives: Guideposts for a Safer Society , 2018 .

[11]  W. Viscusi,et al.  Best Estimate Selection Bias in the Value of a Statistical Life , 2017, Journal of Benefit-Cost Analysis.

[12]  J. Hammitt,et al.  Valuing Reductions in Fatal Illness Risks: Implications of Recent Research. , 2016, Health economics.

[13]  W. Viscusi,et al.  The fatality and morbidity components of the value of statistical life. , 2016, Journal of health economics.

[14]  J. Hammitt,et al.  Research Synthesis and the Value per Statistical Life , 2015, Risk analysis : an official publication of the Society for Risk Analysis.

[15]  W. Viscusi The Role of Publication Selection Bias in Estimates of the Value of a Statistical Life , 2014, American Journal of Health Economics.

[16]  Kip Viscusi Using data from the Census of Fatal Occupational Injuries to estimate the “value of a statistical life” , 2013 .

[17]  Joseph A Hill United States Life Tables , 2013 .

[18]  Maureen Cropper,et al.  Valuing Mortality Risk Reductions: Progress and Challenges , 2011 .

[19]  Trudy Ann Cameron,et al.  Demand for health risk reductions: A cross-national comparison between the U.S. and Canada , 2010 .

[20]  Trudy Ann Cameron,et al.  Euthanizing the Value of a Statistical Life , 2010, Review of Environmental Economics and Policy.

[21]  Lisa A. Robinson,et al.  Journal of Homeland Security and Emergency Management Valuing the Risk of Death from Terrorist Attacks , 2011 .

[22]  Valuing Mortality Risk Reductions for Environmental Policy : A White Paper , 2010 .

[23]  W. Kip Viscusi,et al.  Adjusting the Value of a Statistical Life for Age and Cohort Effects , 2008, The Review of Economics and Statistics.

[24]  Alan Krupnick,et al.  Mortality-risk Valuation and Age: Stated Preference Evidence , 2007 .

[25]  Lisa A. Robinson,et al.  Policy Monitorhow Us Government Agencies Value Mortality Risk Reductions , 2007 .

[26]  W. Kip Viscusi,et al.  Age Differences in the Value of Statistical Life: Revealed Preference Evidence , 2007 .

[27]  G. Salkeld Valuing health for regulatory cost-effectiveness analysis , 2007 .

[28]  Mary F. Evans,et al.  Do We Really Understand the Age-VSL Relationship? , 2006 .

[29]  W. Kip Viscusi,et al.  Labor Market Estimates of the Senior Discount for the Value of Statistical Life , 2006 .

[30]  Kevin M. Murphy,et al.  The Value of Health and Longevity , 2005, Journal of Political Economy.

[31]  Kelly B. Maguire,et al.  Willingness to Pay for Environmental Health Risk Reductions when there are Varying Degrees of Life Expectancy: A White Paper , 2006 .

[32]  Richard J. Zeckhauser,et al.  Survival versus Consumption , 1984 .